Results 151 to 160 of about 276,897 (341)

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung [PDF]

, 2021
Torsten Goldmann, Sebastian Marwitz, Dörte Nitschkowski, Rosemarie Krupar, Max Backman, Hedvig Elfving, Viktoria Thurfjell, Amanda Lindberg, Hans Brunnström, Linnéa La Fleur, Artur Mezheyeuski, Johanna Sofia Margareta Mattsson, Johan Botling, Patrick Micke, Carina Strell   +14 more
openalex   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

PUB147 KRAS Mutants Regulated PD-L1 Expression through NF-ƘB and HIF-1α Pathways in Non-Small Cell Lung Cancer Cells [PDF]

, 2017
Rong Guo, Jie Wang, Hua Bai
openalex   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

397PD KRAS mutation-induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma [PDF]

, 2016
Shaodong Hong, not provided and Wenbiao Chen, W. Fang, Jun Zhan, L. Zhang   +4 more
openalex   +1 more source

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study [PDF]

, 2022
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina‐Cerrillo, Zin Myint, Tomáš Büchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari   +12 more
openalex   +1 more source

Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity

Advanced Science, EarlyView.
Proinflammatory mast cells represent an MHC‐IIhigh, cytokine‐producing mast cell subset associated with improved survival and enhanced responses to anti‐PD‐1 therapy. Retinoic acid drives their polarization, enabling antigen uptake and presentation, and T cell recruitment and activation, collectively promoting adaptive anti‐tumor immunity.
Lizao Zhang, Siqi Ren, Yuhui Li, Rongxi Chen, Ling Qiu, Yongmei Tan, Suling Chen, Huiqian Wu, Lianxi Mai, Xiao Tan, Xin Liu, Peisheng Liang, Shijia Kuang, Liansheng Wang, Jingkang Liu, Jintao Li, Yanyan Li, Qiuping Xu, Yongzhi Su, Yuehai Luo, Binyan Wu, Zijing Huang, Haotian Cao, Qunxing Li, Jinsong Li, Tianjun Lan   +25 more
wiley   +1 more source

Supplementary Figure 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

, 2023
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A. Scolyer   +10 more
openalex   +1 more source

CMTM6 controls PD-L1 [PDF]

Nature Immunology, 2017
openaire   +2 more sources